Mergers & Acquisitions ·
On July 14, 2026, the Nasdaq Hearings Panel denied Sangamo Therapeutics' request to continue its listing on Nasdaq…
SGMOSangamo Therapeutics, Inc
On July 14, 2026, the Nasdaq Hearings Panel denied Sangamo Therapeutics' request to continue its listing on Nasdaq, following a previous suspension on May 5, 2026. The company does not intend to request further review and expects its common stock to be deregistered. Additionally, the U.S. Bankruptcy Court for the District of Delaware entered an order approving bidding procedures for the sale of all or substantially all of the company's assets. Key dates include a bid deadline of August 4, 2026, a potential auction on August 10, 2026, and a sale hearing on August 20, 2026. The company is currently operating as a debtor-in-possession under Chapter 11 bankruptcy. Sangamo Therapeutics is a biotechnology company that develops therapeutic products for the treatment of diseases.